Wide Spectral Range Photonic Glucometer

Projektinformationen

WASP

ID Finanzhilfevereinbarung: 680894

DOI

10.3030/680894

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Juli 2015

Startdatum 1 November 2015

Enddatum 30 April 2017

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 149 972,00

EU-Beitrag

€ 149 972,00

Koordiniert durch

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain

Periodic Reporting for period 1 - WASP (Wide Spectral Range Photonic Glucometer)

Berichtszeitraum: 2015-11-01 bis 2017-04-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Diabetic patients (around 8.6% of the western population) must constantly monitor their blood glucose level (BGL) with a continuous glucose monitoring (CGM) device. This social need has already been addressed by some companies, with an overall compound annual growth rate (CAGR) for this market (from 2014 through 2019) of 19.6%. Besides such highly attractive market possibilities, to date none of the commercial CGMs can provide accuracy below 20%. This is a non-assumable risk for the users. In addition, the readout medical device can only be used for glucose sensing, severely limiting its application for early detection of analytes of interest.
WASP POC has aimed this unmeet societal need by the development of the next generation of CGMs which makes use of light as interrogation mechanism. In this approach, and with the appropriate multi-purpose medical readout device, accuracies of 5% have been attained -as opposite to the 20% in commercially available systems- Additionally, they require very small (ul) volume samples and having a similar response time.
As an additional achievement of this project whose applicability is far beyond CGMs, a chip-to-world interface has been developed, which solves the major issues related to photonic circuits applied to biological monitoring: the robust and stable fiber optics alignment.